- In recent days, Haemonetics Corporation saw increased attention as sector-wide interest in medical devices coincided with internal changes, including areshaped reporting segments and updated leadership compensation estimates for President and CEO Christopher A. Simon of US$12,044,701 for 2026.
- Investors are weighing this mix of sector momentum, perceptions of modest undervaluation, and Haemonetics’ consolidation of its Plasma and Blood Center units into a single Apheresis segment as they reassess the company’s fundamentals and outlook.
- With renewed medical device sector interest and Haemonetics’ recent segment reorganization, we’ll examine how this news reshapes its investment narrative.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
Haemonetics Investment Narrative Recap
To own Haemonetics, you have to believe its core plasma, apheresis, and vascular closure technologies can support durable demand despite earnings volatility and U.S. concentration. The recent sector rally, CEO pay estimates, and modestly higher government awards do not materially change the near term focus on improving profitability after a year of weaker margins, or the key risk that dependence on a few U.S. products leaves results exposed if growth in areas like VASCADE stalls.
The most relevant update here is Haemonetics’ decision to merge its Plasma and Blood Center units into a single Apheresis segment while renaming Hospital as MedSurg. This change should make it easier for you to track how well management is addressing execution issues in its core franchises, especially as analysts are watching for clearer progress on margins and the balance between U.S. exposure and international opportunities.
Yet behind the recent share price strength, investors should be aware that growing competition in vascular closure could...
Read the full narrative on Haemonetics (it's free!)
Haemonetics' narrative projects $1.5 billion revenue and $247.6 million earnings by 2029.
Uncover how Haemonetics' forecasts yield a $86.90 fair value, a 10% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranking analysts are far more cautious than the consensus, even before this news, assuming revenue reaches about US$1.5 billion and earnings roughly US$254.6 million by 2029, and worrying that rising competition in Vascular Closure could blunt Haemonetics’ recent share price gains.
Explore 2 other fair value estimates on Haemonetics - why the stock might be worth as much as 60% more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Haemonetics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Haemonetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Haemonetics' overall financial health at a glance.
Curious About Other Options?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com